Cargando…
Satisfying QTPP of Erythropoietin Biosimilar by QbD through DoE-Derived Downstream Process Engineering
Well-characterized and scalable downstream processes for the purification of biologics are extremely demanding for delivering quality therapeutics to patients at a reasonable price. Erythropoietin (EPO) is a blockbuster biologic with diverse clinical applications, but its application is limited to f...
Autores principales: | Nag, Kakon, Sarker, Enamul Haq, Kumar, Samir, Chakraborty, Sourav, Khan, Maksusdur Rahman, Chowdhury, Mashfiqur Rahman, Roy, Rony, Roy, Ratan, Biswas, Bipul Kumar, Bappi, Emrul Hasan, Mohiuddin, Mohammad, Sultana, Naznin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460001/ https://www.ncbi.nlm.nih.gov/pubmed/37631301 http://dx.doi.org/10.3390/pharmaceutics15082087 |
Ejemplares similares
-
QbD Based Media Development for the Production of Fab Fragments in E. coli
por: Kumar, Deepak, et al.
Publicado: (2019) -
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
por: Zurdo, Jesús, et al.
Publicado: (2015) -
Pharmaceutical Development and Design of Thermosensitive Liposomes Based on the QbD Approach
por: Dobó, Dorina Gabriella, et al.
Publicado: (2022) -
QbD Enabled Azacitidine Loaded Liposomal Nanoformulation and Its In Vitro Evaluation
por: Kesharwani, Prashant, et al.
Publicado: (2021) -
An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
por: Németh, Zsófia, et al.
Publicado: (2021)